Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Liguria – page 62

810 clinical trials in Liguria, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Liguria at a glance
810
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

810 trials in Liguria

Open in trial search

Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lecanemab
  • Sponsor:Eisai Limited

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of LT3001 for Patients with Acute Ischemic Stroke

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:LT3001
  • Sponsor:Lumosa Therapeutics Co. Ltd.

Study Comparing Linvoseltamab to Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Safety and Effects of Fenfluramine in Infants Aged 1 to Less Than 2 Years with Dravet Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Cystic fibrosis

Not recruiting

Study on VX-522 and Ivacaftor for Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Effects of Romosozumab and Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Calcium
  • Sponsor:Amgen Inc.

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of RO7434656 for Patients with Primary IgA Nephropathy at High Risk of Progression

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 696844
  • Sponsor:F. Hoffmann-La Roche AG

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Liguria

What the registry says about research in the country

01 HIV Treatment Research

Clinical research focusing on early treatment switching strategies for HIV-1 infected individuals who have achieved viral suppression. The trials examine the effectiveness of transitioning from three-drug to two-drug antiretroviral therapy.

  • Viral Suppression Maintenance
  • Treatment Simplification
  • Long-term Safety Assessment

The study aims to evaluate a novel approach using dolutegravir/lamivudine combination therapy, potentially offering patients a more streamlined treatment regimen while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.